AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results
By Larissa Warneck-Silvestrin
AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3...
Eli Lilly invests $3bn in injectable drug manufacturing facility
Mitsubishi teams up with Dewpoint in $480m ALS deal
PTC Therapeutics boosted by Novartis rights deal for Huntington’s...
Novocure reports positive phase 3 results for tumor treating fields...
Portugal’s Hovione builds spray drying capacity in US and Ireland
→
→
→
→